A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2

Antzeko izenburuak

• A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1
  nork: Park, Cheol-Kyu, et al.
  Argitaratua: (2021)
• Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
  nork: Mok, T.S., et al.
  Argitaratua: (2016)
• The different path of T790M-positive EGFR-mutant lung cancer
  nork: Yoon, Shinkyo, et al.
  Argitaratua: (2018)
• Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
  nork: Sakai, Hitomi, et al.
  Argitaratua: (2017)
• EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
  nork: Li, Chenguang, et al.
  Argitaratua: (2018)